<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971356</url>
  </required_header>
  <id_info>
    <org_study_id>CAGE-FREE II</org_study_id>
    <nct_id>NCT04971356</nct_id>
  </id_info>
  <brief_title>1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon</brief_title>
  <acronym>CAGEFREEII</acronym>
  <official_title>Aspirin Plus Ticagrelor for 1 Month Followed by 5 Months Ticagrelor Monotherapy Versus Aspirin Plus Ticagrelor for 12 Months in Acute Coronary Syndrome Patients With Drug-coated Balloon: a Multicentre, Randomized, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-Coated Balloon (DCB) angioplasty is similar to plain old balloon angioplasty&#xD;
      procedurally, but there is an anti-proliferative medication paclitaxel coated to the balloon.&#xD;
      Treating ISR lesions with the DCB has the theoretical advantage of avoiding multiple stent&#xD;
      layers and respecting the vessel anatomy. DCB has shown promising results for the treatment&#xD;
      of ISR. Currently, DCB has a Class I indication to treat ISR recommended by European Society&#xD;
      of Cardiology guidelines. In addition, some interventional cardiologist has also applied DCB&#xD;
      in de novo lesions in their clinical practice.&#xD;
&#xD;
      Bleeding after PCI remains a substantial clinical problem. Bleeding post-PCI increases the&#xD;
      risk of adverse outcomes such as death, non-fatal myocardial infarction, and prolongs&#xD;
      hospital stay. Clinical data has suggested that major bleeding post-PCI would increase the&#xD;
      risk of mortality 5.7-fold. The antiplatelet medications are the major cause of bleeding&#xD;
      events post-PCI.&#xD;
&#xD;
      Current guidelines for stents recommended DAPT of aspirin plus a P2Y12 inhibitor for at least&#xD;
      12 months after stent implantation in patients with the acute coronary syndrome. Compared&#xD;
      with the DES, because of the absence of metal inside the coronary artery, the use of DCB&#xD;
      might theoretically allow shorter duration antiplatelet therapy. However, the optimal course&#xD;
      of DAPT for the DCB treated patients remains controversial.&#xD;
&#xD;
      In 2013, the consensus from the German group suggested that for the acute coronary syndrome,&#xD;
      DAPT should be used for 12 months. The consensus of DAPT developed by the European Society of&#xD;
      Cardiology (ESC) in 2017 stated that &quot;in patients treated with DCB, dedicated clinical trials&#xD;
      investigating the optimal duration of DAPT are lacking.&quot; So far, there are no randomized data&#xD;
      showing the optimal DAPT duration for the DCB treated patients.&#xD;
&#xD;
      In the current study, we use Aspirin + Ticagrelor for 1-month followed by Ticagrelor&#xD;
      monotherapy for 5-month, afterward, Aspirin monotherapy for 6 months to be the antiplatelet&#xD;
      regimen in the experimental arm, to compare with the Reference arm, which is Aspirin +&#xD;
      Ticagrelor for 12-month in a non-inferiority statistical assumption, aiming to investigate&#xD;
      the optimal duration of the DAPT in ACS patients after DCB treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net adverse clinical events (NACE)</measure>
    <time_frame>12 months</time_frame>
    <description>NACE is a composite clinical endpoint of all-cause death, any stroke, any MI, any revascularization and BARC type 3 or 5 bleeding events</description>
  </primary_outcome>
  <other_outcome>
    <measure>BARC type 3 or 5 bleeding events</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Bleeding events type 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>BARC type 2 ,3 or 5 bleeding events</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Bleeding events type 2, 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>BARC defined type 2 bleeding events</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Bleeding events type 2 defined by BARC (Bleeding Academic Research Consortium) criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of NACE</measure>
    <time_frame>1 months</time_frame>
    <description>NACE is a composite clinical endpoint of all-cause death, any stroke, any MI, any revascularization and BARC type 3 or 5 bleeding events</description>
  </other_outcome>
  <other_outcome>
    <measure>Device-oriented Composite Endpoint (DoCE)</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>DoCE is a composite clinical endpoint of cardiac cause death, target vessel myocardial infraction (TV-MI), and Clinically individual target lesion revascularization (CI-TLR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Rates of individual components of DoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Target vessel myocardial infraction (TV-MI)</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Rates of individual components of DoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically individual target lesion revascularization (CI-TLR)</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Rates of individual components of DoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient-oriented Composite Endpoint (PoCE)</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>PoCE defined as all-cause death, any stroke, any MI, any revascularization</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause death</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Rates of individual components of PoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Any MI</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Rates of individual components of PoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Any stroke</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Rates of individual components of PoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Any revascularization</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Rates of individual components of PoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Target vessel failure is defined as cardiovascular death, target vessel myocardial infraction (TV-MI), and clinically-indicated target vessel revascularization</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-indicated target vessel revascularization</measure>
    <time_frame>1 and 12 months</time_frame>
    <description>Rates of individual components of TVF</description>
  </other_outcome>
  <other_outcome>
    <measure>Definite/Probable stent thrombosis rates</measure>
    <time_frame>1 and 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1908</enrollment>
  <condition>Antiplatelet Drug</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Angioplasty, Balloon</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-month of Aspirin + Ticagrelor, followed by 5-month of Ticagrelor monotherapy; Afterward, Aspirin monotherapy for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12-month Aspirin plus Ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100mg for 1-month (immediately after PCI)</intervention_name>
    <description>Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg for 6-month (immediately after PCI)</intervention_name>
    <description>Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100mg for 6-month (6-month post PCI)</intervention_name>
    <description>Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100mg for 12-month (immediately after PCI)</intervention_name>
    <description>Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm</description>
    <arm_group_label>Reference arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg for 12-month (immediately after PCI)</intervention_name>
    <description>Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm</description>
    <arm_group_label>Reference arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with an indication for PCI due to acute coronary syndrome&#xD;
&#xD;
          2. All target lesions can be successful treatment of PCI with drug-coated balloon (DCB)&#xD;
&#xD;
          3. Patients who are able to complete the follow-up and compliant to the prescribed&#xD;
             medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under the age of 18 or Older than 80 years old&#xD;
&#xD;
          2. Unable to give informed consent&#xD;
&#xD;
          3. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed&#xD;
             within 7 days prior to the index procedure in women of child-bearing potential&#xD;
             according to local practice)&#xD;
&#xD;
          4. Known contraindication to medications such as Heparin, antiplatelet drugs, or&#xD;
             contrast.&#xD;
&#xD;
          5. Currently participating in another trial and not yet at its primary endpoint&#xD;
&#xD;
          6. Planned elective surgery&#xD;
&#xD;
          7. Concurrent medical condition with a life expectancy of less than 1 years&#xD;
&#xD;
          8. Previous intracranial haemorrhage&#xD;
&#xD;
          9. Need long-term oral anticoagulant therapy&#xD;
&#xD;
         10. Cardiogenic shock&#xD;
&#xD;
         11. Previous stent implantation 6 month&#xD;
&#xD;
         12. In-stent thrombosis&#xD;
&#xD;
         13. Target lesion located in surgical conduit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Tao, MD,PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Serruys, MD,PHD</last_name>
    <role>Study Chair</role>
    <affiliation>National University of Ireland Galway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshinobu Onuma, MD,PHD</last_name>
    <role>Study Chair</role>
    <affiliation>National University of Ireland Galway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chao Gao, MD,PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chao Gao, MD,PHD</last_name>
    <phone>+86-18629551066</phone>
    <email>woshigaochao@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Running, BSc</last_name>
    <phone>+86-15802990370</phone>
    <email>running-zhang@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ling Tao</name>
      <address>
        <city>Xi'an</city>
        <state>Shannxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>LingTao</investigator_full_name>
    <investigator_title>Professor in cardiology, Director of the department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Ticagrelor Monotherapy</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Drug-coated balloons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

